Corticosteroids for acute traumatic brain injury

Area of Science:

• Neuroscience
• Clinical Medicine
• Pharmacology

Background:

• Traumatic brain injury (TBI) is a significant cause of mortality and long-term disability.
• Corticosteroids have been historically employed in the management of acute TBI.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of corticosteroid administration in patients with acute traumatic brain injury.
• To synthesize evidence from randomized controlled trials regarding corticosteroid treatment for TBI.

Main Methods:

• A comprehensive literature search was conducted across multiple electronic databases (MEDLINE, EMBASE, Cochrane Library) up to October 2004.
• Included were randomized controlled trials (RCTs) assessing corticosteroid use in acute TBI with adequate or unclear allocation concealment.
• Data extraction focused on participant numbers, follow-up duration, mortality, disability, infection rates, and gastrointestinal bleeding.

Main Results:

• Twenty RCTs involving 12,303 participants were identified.
• The largest trial, comprising 80% of participants, indicated a significant increase in mortality risk with steroid use (Risk Ratio: 1.18; 95% CI: 1.09–1.27).
• Pooled analysis for death or severe disability showed a relative risk of 1.01 (0.91–1.11), while infection risk was 1.03 (0.99–1.07), and gastrointestinal bleeding risk was 1.23 (0.91–1.67).

Conclusions:

• The substantial increase in mortality observed in the largest trial warrants careful consideration.
• Current evidence suggests that corticosteroids should not be routinely administered to patients with acute traumatic brain injury.
• Discontinuation of routine corticosteroid use in TBI management is recommended based on safety and efficacy data.